Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05265429 · ClinicalTrials.gov registry record
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
A clinical trial of Non-Small Cell Lung Cancer and Small Cell Lung Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 500
- Enrollment target
- 4
- Study locations
NCT05265429 is a study of Non-Small Cell Lung Cancer and Small Cell Lung Carcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 500 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (24% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT05265429, a study of Non-Small Cell Lung Cancer and Small Cell Lung Carcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Conditions Studied
Interventions
- GENETIC Data and Specimen Collection
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05265429
The ClinicalTrials.gov registry entry for NCT05265429 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (24% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Data and Specimen Collection is the first listed.
NCT05265429 reports 4 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05265429 about?
NCT05265429 is a clinical study titled "Biology of Young Lung Cancer Study: The YOUNG LUNG Study". The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
What is the current status of trial NCT05265429?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-01-01. Estimated completion is 2027-08-01.
What conditions does trial NCT05265429 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma.
What interventions are being tested in trial NCT05265429?
The interventions under investigation include: Data and Specimen Collection (GENETIC).
Who is sponsoring clinical trial NCT05265429?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05265429 being conducted?
This trial has 4 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Non-Small Cell Lung Cancer
All registered trials for this condition
Small Cell Lung Carcinoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.